Remus Pharmaceuticals Valuation

Is REMUS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of REMUS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: REMUS (₹2360) is trading above our estimate of fair value (₹100.43)

Significantly Below Fair Value: REMUS is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for REMUS?

Key metric: As REMUS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for REMUS. This is calculated by dividing REMUS's market cap by their current earnings.
What is REMUS's PE Ratio?
PE Ratio	46.5x
Earnings	₹299.01m
Market Cap	₹13.91b

REMUS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3x
Enterprise Value/EBITDA	34.5x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does REMUS's PE Ratio compare to its peers?

The above table shows the PE ratio for REMUS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	42x
DENTALKART Vasa Denticity	56.9x	n/a	₹10.0b
BALAXI Balaxi Pharmaceuticals	11.1x	n/a	₹3.9b
ENTERO Entero Healthcare Solutions	79.3x	49.9%	₹56.7b
QMSMEDI QMS Medical Allied Services	20.6x	n/a	₹2.0b
REMUS Remus Pharmaceuticals	46.5x	n/a	₹13.9b

Price-To-Earnings vs Peers: REMUS is expensive based on its Price-To-Earnings Ratio (46.5x) compared to the peer average (42x).

Price to Earnings Ratio vs Industry

How does REMUS's PE Ratio compare vs other companies in the IN Healthcare Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap
523696 Fortis Malar Hospitals	2.1x	n/a	US$11.76m

No more companies available in this PE range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: REMUS is expensive based on its Price-To-Earnings Ratio (46.5x) compared to the Indian Healthcare industry average (41.9x).

Price to Earnings Ratio vs Fair Ratio

What is REMUS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

REMUS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	46.5x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate REMUS's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Mohini Health & Hygiene

₹875.3m

Engages in the manufacture and sale of health and hygiene products in India.

MHHL

₹48.00

-4.9%

-28.0%

Dr Lalchandani Labs

₹78.0m

Provides diagnostic and related healthcare tests and services in India.

541299

₹18.00

n/a

N G Industries

₹547.0m

Provides various healthcare services in India.

530897

₹163.25

-2.7%

-2.5%